Journal for ImmunoTherapy of Cancer (Nov 2020)
317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors
Abstract
No abstracts available.